CU24486B1 - Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla - Google Patents
Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararlaInfo
- Publication number
- CU24486B1 CU24486B1 CU2016000144A CU20160144A CU24486B1 CU 24486 B1 CU24486 B1 CU 24486B1 CU 2016000144 A CU2016000144 A CU 2016000144A CU 20160144 A CU20160144 A CU 20160144A CU 24486 B1 CU24486 B1 CU 24486B1
- Authority
- CU
- Cuba
- Prior art keywords
- tablets
- prepare
- understanding
- same
- solid dispersion
- Prior art date
Links
- 229940123237 Taxane Drugs 0.000 title abstract 2
- 239000007962 solid dispersion Substances 0.000 title abstract 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title abstract 2
- 239000006185 dispersion Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 239000008180 pharmaceutical surfactant Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>La presente invención provee una dispersión sólida amorfa que comprende un taxano o una sal del mismo aceptable desde el punto de vista farmacéutico, un polímero aceptable desde el punto de vista farmacéutico, y un agente tensoactivo aceptable desde el punto de vista farmacéutico, Ia cual tiene solubilidad mejorada. También se provee un método para Ia preparación de Ia dispersión sólida. La presente invención también provee una tableta que tiene buena solubilidad, biodisponibilidad y estabilidad, que comprende Ia dispersión sólida amorfa, un excipiente intragranular, y un excipiente extragranular.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2014/002734 WO2015152433A1 (en) | 2014-03-31 | 2014-03-31 | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
PCT/KR2015/002756 WO2015152544A1 (en) | 2014-03-31 | 2015-03-20 | Amorphous solid dispersion comprising taxane, tablet comprising the same, and method for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CU24486B1 true CU24486B1 (es) | 2020-11-30 |
Family
ID=54240734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2016000144A CU24486B1 (es) | 2014-03-31 | 2015-03-20 | Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla |
Country Status (33)
Country | Link |
---|---|
US (1) | US9867801B2 (es) |
EP (1) | EP3125872B1 (es) |
JP (1) | JP6539675B2 (es) |
KR (1) | KR101851571B1 (es) |
CN (1) | CN106255496B (es) |
AR (1) | AR099886A1 (es) |
AU (1) | AU2015242738B2 (es) |
BR (1) | BR112016022528B1 (es) |
CA (1) | CA2944438C (es) |
CL (1) | CL2016002441A1 (es) |
CU (1) | CU24486B1 (es) |
DK (1) | DK3125872T3 (es) |
DO (1) | DOP2016000262A (es) |
ES (1) | ES2748686T3 (es) |
GT (1) | GT201600208A (es) |
HU (1) | HUE046616T2 (es) |
IL (1) | IL247977B (es) |
LT (1) | LT3125872T (es) |
MA (1) | MA39361B1 (es) |
MX (1) | MX2016012596A (es) |
MY (1) | MY175387A (es) |
PE (1) | PE20161477A1 (es) |
PH (1) | PH12016501825A1 (es) |
PL (1) | PL3125872T3 (es) |
PT (1) | PT3125872T (es) |
RU (1) | RU2684632C2 (es) |
SA (1) | SA516371952B1 (es) |
SG (1) | SG11201607456RA (es) |
SI (1) | SI3125872T1 (es) |
TW (1) | TWI706793B (es) |
UA (1) | UA117610C2 (es) |
UY (1) | UY36055A (es) |
WO (2) | WO2015152433A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017091373A1 (en) * | 2015-11-25 | 2017-06-01 | Patheon Development Services Inc. | Amorphous dispersion granules and oral dosage forms |
CN109069460A (zh) * | 2016-05-09 | 2018-12-21 | 分散技术有限责任公司 | 改进的药物制剂 |
CN106955288B (zh) * | 2017-03-30 | 2020-01-10 | 复旦大学附属中山医院 | Fxr激动剂在制备治疗脂肪肉瘤相关疾病药物中的用途 |
TWI833710B (zh) * | 2017-10-06 | 2024-03-01 | 香港商慧源香港創新有限公司 | 高單位含量口服型紫杉烷組合物及方法 |
CN111511365A (zh) * | 2017-11-10 | 2020-08-07 | 分散技术有限责任公司 | 改进的药物制剂 |
KR20210120039A (ko) * | 2019-01-25 | 2021-10-06 | 베이진 엘티디 | B-raf 키나제 이합체 억제제의 안정적인 고체 분산액, 이의 제조 방법 및 용도 |
CN109851593B (zh) * | 2019-02-01 | 2021-04-16 | 沈阳药科大学 | 基于淋巴介导转运的甘油三酯前药及其制备方法 |
CN110105368B (zh) * | 2019-05-09 | 2022-01-07 | 上海大学 | 去氧紫杉烷类似物及其制备方法 |
WO2021177930A1 (en) * | 2020-03-06 | 2021-09-10 | Vyshnevskyy Ihor Anatoliyovych | Pharmaceutical composition with increased solubility of gesperidine and method of its preparation |
CN116964044A (zh) | 2020-10-07 | 2023-10-27 | 希华医药有限公司 | 乙酰胺基-苯基四唑衍生物及其使用方法 |
EP4358942A1 (en) * | 2021-06-23 | 2024-05-01 | Blueprint Medicines Corporation | Pharmaceutical compositions of an epidermal growth factor receptor inhibitor |
WO2023154171A1 (en) * | 2022-02-14 | 2023-08-17 | Purdue Research Foundation | Polymer salts for improved drug delivery from amorphous solid dispersions |
AU2022368370A1 (en) * | 2022-03-08 | 2023-09-28 | Cnpharm Co., Ltd. | Pharmaceutical composition containing docetaxel or pharmaceutically acceptable salt thereof and preparation method therefor |
CN115429766B (zh) * | 2022-09-08 | 2023-10-27 | 江苏集萃新型药物制剂技术研究所有限公司 | 淫羊藿苷固体分散体、复方药物双层片剂及其制备方法与应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2294981C (en) | 1997-06-27 | 2012-04-03 | Vivorx Pharmaceuticals, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
US6610317B2 (en) | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
KR20030041577A (ko) * | 2001-11-20 | 2003-05-27 | 디디에스텍주식회사 | 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물 |
CA2540104A1 (en) * | 2003-09-30 | 2005-04-07 | Solubest Ltd. | Water soluble nanoparticles comprising inclusion complexes |
WO2006046623A1 (ja) * | 2004-10-25 | 2006-05-04 | Japan Tobacco Inc. | 溶解性及び安定性の改善された固形製剤及びその製造方法 |
CN1840196A (zh) * | 2006-01-27 | 2006-10-04 | 无锡杰西医药科技有限公司 | 一种适用于难溶性药物的分散剂 |
CN101340896A (zh) * | 2005-12-22 | 2009-01-07 | 特瓦制药工业有限公司 | 含有低溶解性药物的压缩的固体剂型和其制备方法 |
US9833510B2 (en) * | 2007-06-12 | 2017-12-05 | Johnson & Johnson Consumer Inc. | Modified release solid or semi-solid dosage forms |
US9089544B2 (en) * | 2007-08-24 | 2015-07-28 | Slotervaart Participaties Bv | Composition |
GB0716591D0 (en) | 2007-08-24 | 2007-10-03 | Vereniging Het Nl Kanker I | Composition |
CA2696622C (en) * | 2007-08-24 | 2016-07-19 | Stichting Het Nederlands Kanker Instituut | Compositions for the treatment of neoplastic diseases |
WO2010020799A2 (en) * | 2008-08-22 | 2010-02-25 | Slotervaart Participaties Bv | Composition |
BRPI0906467C1 (pt) * | 2008-01-25 | 2021-05-25 | Gruenenthal Gmbh | forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada |
CN101632630A (zh) * | 2008-07-24 | 2010-01-27 | 北京诺美医药科技有限公司 | 一种普罗布考固体分散体 |
JP5751868B2 (ja) * | 2010-03-30 | 2015-07-22 | 日東電工株式会社 | フィルム状製剤及びその製造方法 |
MX2012014387A (es) * | 2010-06-09 | 2013-05-01 | Abbvie Inc | Dispersiones solidas que contienen inhibidores de cinasa. |
MX347512B (es) * | 2010-11-19 | 2017-04-28 | Gilead Sciences Inc | Composiciones terapeuticas que comprenden hcl de rilpivirina y fumarato de disoproxilo de tenofovir. |
WO2013040187A1 (en) * | 2011-09-13 | 2013-03-21 | Isp Investments Inc. | Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer |
CN102357075A (zh) * | 2011-09-30 | 2012-02-22 | 武汉平华生物医药科技有限公司 | 一种多西他赛纳米制剂及其制备方法 |
-
2014
- 2014-03-31 WO PCT/KR2014/002734 patent/WO2015152433A1/en active Application Filing
-
2015
- 2015-03-20 PL PL15773354T patent/PL3125872T3/pl unknown
- 2015-03-20 CA CA2944438A patent/CA2944438C/en active Active
- 2015-03-20 PT PT157733544T patent/PT3125872T/pt unknown
- 2015-03-20 EP EP15773354.4A patent/EP3125872B1/en active Active
- 2015-03-20 KR KR1020167027373A patent/KR101851571B1/ko active IP Right Grant
- 2015-03-20 RU RU2016136636A patent/RU2684632C2/ru active
- 2015-03-20 MX MX2016012596A patent/MX2016012596A/es active IP Right Grant
- 2015-03-20 LT LTEP15773354.4T patent/LT3125872T/lt unknown
- 2015-03-20 HU HUE15773354A patent/HUE046616T2/hu unknown
- 2015-03-20 WO PCT/KR2015/002756 patent/WO2015152544A1/en active Application Filing
- 2015-03-20 PE PE2016001849A patent/PE20161477A1/es unknown
- 2015-03-20 BR BR112016022528-7A patent/BR112016022528B1/pt active IP Right Grant
- 2015-03-20 MA MA39361A patent/MA39361B1/fr unknown
- 2015-03-20 US US15/300,515 patent/US9867801B2/en active Active
- 2015-03-20 DK DK15773354.4T patent/DK3125872T3/da active
- 2015-03-20 ES ES15773354T patent/ES2748686T3/es active Active
- 2015-03-20 CN CN201580016355.2A patent/CN106255496B/zh active Active
- 2015-03-20 MY MYPI2016001721A patent/MY175387A/en unknown
- 2015-03-20 AU AU2015242738A patent/AU2015242738B2/en active Active
- 2015-03-20 JP JP2016559161A patent/JP6539675B2/ja active Active
- 2015-03-20 SI SI201530891T patent/SI3125872T1/sl unknown
- 2015-03-20 CU CU2016000144A patent/CU24486B1/es unknown
- 2015-03-20 SG SG11201607456RA patent/SG11201607456RA/en unknown
- 2015-03-20 UA UAA201609267A patent/UA117610C2/uk unknown
- 2015-03-27 UY UY0001036055A patent/UY36055A/es not_active Application Discontinuation
- 2015-03-30 TW TW104110283A patent/TWI706793B/zh active
- 2015-03-30 AR ARP150100942A patent/AR099886A1/es unknown
-
2016
- 2016-09-19 PH PH12016501825A patent/PH12016501825A1/en unknown
- 2016-09-22 IL IL247977A patent/IL247977B/en active IP Right Grant
- 2016-09-27 DO DO2016000262A patent/DOP2016000262A/es unknown
- 2016-09-28 CL CL2016002441A patent/CL2016002441A1/es unknown
- 2016-09-29 SA SA516371952A patent/SA516371952B1/ar unknown
- 2016-09-30 GT GT201600208A patent/GT201600208A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU24486B1 (es) | Dispersión sólida amorfa que comprende taxano, tabletas comprendiendo la misma y método para prepararla | |
CR20160438A (es) | Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación | |
NZ734233A (en) | Pharmaceutical compositions comprising meloxicam | |
MA41265A (fr) | Compositions pour administration de médicaments iléo-jéjunal. | |
MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
EP3215806A4 (en) | 3d imaging, ranging, and/or tracking using active illumination and point spread function engineering | |
CL2016001587A1 (es) | Derivado basado en 1,2-naftoquinona y método de preparación del mismo. | |
EP3102188A4 (en) | Novel disintegration systems for pharmaceutical dosage forms | |
PH12016501841A1 (en) | Immunosuppressant formulation | |
EP3389628A4 (en) | PHARMACEUTICAL FORMULATIONS OF MOUSE CHEESE TABLETS | |
EA201691670A1 (ru) | Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2 | |
CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
MX2017003644A (es) | Formulaciones eutecticas de clorhidrato de ciclobenzaprina. | |
CR20150297A (es) | Producto de comicronización que comprende acetato de ulipristal | |
EP3556345A4 (en) | Mouth-breaking tablet with carbamate compound | |
MX2016015261A (es) | Dispersion solida de allisartan isoproxilo y su composicion. | |
EP3202417A4 (en) | Vaccine pharmaceutical composition for transdermal administration | |
EP3471708A4 (en) | STABLE PHARMACEUTICAL COMPOSITIONS WITH ORAL DISINTEGRATION | |
EP3240532A4 (en) | Processes for producing pharmaceutical excipients from lignocellulosic biomass, and pharmaceutical excipients obtained therefrom | |
MX2021003230A (es) | Composiciones farmaceuticas que comprenden meloxicam. | |
MX2017015322A (es) | Composicion farmaceutica oral de isotretinoin. | |
WO2014125504A3 (en) | Pharmaceutical compositions of febuxostat | |
BR112017019364A2 (pt) | dispersões sólidas | |
EA201691422A1 (ru) | Перорально распадающиеся таблетированные составы мемантина |